Compare PDLB & PGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PDLB | PGEN |
|---|---|---|
| Founded | 1960 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 469.5M | 1.6B |
| IPO Year | 2021 | 2013 |
| Metric | PDLB | PGEN |
|---|---|---|
| Price | $19.20 | $4.76 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $8.33 |
| AVG Volume (30 Days) | 85.6K | ★ 4.9M |
| Earning Date | 04-24-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 160.87 | N/A |
| EPS | ★ 0.36 | N/A |
| Revenue | N/A | ★ $230,981,000.00 |
| Revenue This Year | N/A | $1,115.92 |
| Revenue Next Year | N/A | $81.04 |
| P/E Ratio | $53.72 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.65 | $1.40 |
| 52 Week High | $19.65 | $5.47 |
| Indicator | PDLB | PGEN |
|---|---|---|
| Relative Strength Index (RSI) | 60.19 | 64.27 |
| Support Level | $15.93 | $3.96 |
| Resistance Level | $19.42 | $5.06 |
| Average True Range (ATR) | 0.56 | 0.29 |
| MACD | -0.01 | 0.10 |
| Stochastic Oscillator | 75.91 | 94.24 |
Ponce Financial Group Inc, is a United States-based holding company. Its business consists of taking deposits from the general public and investing those deposits, together with funds generated from operations, in mortgage loans, consisting of one-to-four-family residential, multi-family residential, non-residential property and construction and land, and, to a lesser extent, business, and consumer loans. The company also invests in securities, which consists of securities issued by the U.S. Government and federal agencies and mortgage-backed securities issued by the United States government-sponsored enterprises. Some of the products and services include checking solutions, online and mobile banking, merchant credit card services, and others.
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.